MR
Merck & Co.
MRK · NYSE
$150.32 -1.33% (-$2.02)
1M +16.92%
Market Cap $376.2B
P/E Ratio 118.56x
Div. Yield 2.21%
ROE 6.60%
Bulios Fair Price
$152.08
1.2% upside
Current Price
$150.32
Undervalued Fair Value Overvalued
According to Bulios Fair Price, MRK is currently trading close to its fair value. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
21 /100
Expensive P/FCF 23.42x
P/S 5.67x
P/B 8.97x
Growth
34 /100
Stable Rev. growth 3.08%
FCF growth 5.63%
Book val. growth 4.58%
Profitability
78 /100
Strong Net margin 4.78%
Op. margin 16.65%
FCF margin 24.19%
Quality
31 /100
Poor ROE 6.60%
ROA 2.44%
Asset turnover 0.51x
Debt
46 /100
Moderate Current ratio 1.32x
Int. coverage 5.71x
Net debt/EBITDA 3.40x
Stability
47 /100
Moderate Rev. volatility 3.15%
EPS volatility 2,748.15%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MRK
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Robert Davis
Employees
74,000
Headquarters
Rahway
Upcoming events
15 SEP
Ex-Dividend
Ex-dividend date
07 OCT
Dividend Payment
Payment date
29 OCT
Earnings
Upcoming earnings report